Month: May 2024

First Quarter 2024 Highlighted by Total Revenue Growth of 4% to $19.5 Million NEW PORT RICHEY, Fla., May 15, 2024 (GLOBE NEWSWIRE) — Zeo Energy Corp. (Nasdaq: ZEO) (“Zeo”, “Zeo Energy”, or the “Company”), a leading Florida-based provider of residential solar and energy efficiency solutions, today reported financial results for the first quarter ended March 31, 2024. Recent Financial and Operational HighlightsTotal revenue for the first quarter 2024 increased 4% to $19.5 million year-over-year Gross profit for the first quarter 2024 decreased 47% to $1.8 million year-over-year Adjusted EBITDA for the first quarter 2024 resulted in a loss of $1.2 million Completed merger with ESGEN Acquisition Corp. on March 13, 2024 (the “Business Combination”), resulting in shares and warrants trading on the Nasdaq Capital Market under the...

Q1 2024 Total Revenue increased 145% Y/Y and 34% Q/Q Q1 Co-Location Business Revenue increased 90% Y/Y and 83% Q/Q Q1 Energy Management Business Revenue increased 461% Y/Y and 2% Q/Q Company optimized and reduced Q1 SG&A expenses by 30% Y/Y and 19% Q/Q MIDLAND, Pa., May 15, 2024 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson”, “the Company”), a digital infrastructure company, today announced its unaudited financial and operational results for the first quarter of fiscal year 2024 ended March 31, 2024. “We are delighted with the overall revenue increase during the first quarter of 2024 —145% year-on-year growth and 34% quarter-on-quarter growth, in addition to our progressing the Company’s strategic, operational, and technological plans in Q1, 2024,” said Rahul Mewawalla, CEO and President of Mawson....

Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in the third quarter of 2024 AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Aileron Therapeutics, Inc. (“Aileron” or the “Company”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today reported financial results for the first quarter ended March 31, 2024, and provided a business update. “In the first quarter, we made steady progress against our key priorities of advancing LTI-03 and generating data from Cohort 1 in IPF,”...

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024. Recent Company HighlightsMTEM presented clinical data at the 2024 AACR Annual Meeting that demonstrated MT-6402’s tolerable safety and promising efficacy profile in relapsed/refractory HNSCC patients. As monotherapy in 7 evaluable HNSCC patients (all heavily pretreated and checkpoint experienced), 2 confirmed PRs (ongoing at 10 and 20 months, respectively) and 4 SDs (two of whom showed...

NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) —  XWELL, Inc. (Nasdaq: XWEL) (“XWELL” or the “Company”), an authority in wellness solutions for people on the go, today reported results for the first quarter ended March 31, 2024. Recent Highlights:XWELL delivered 2024 first quarter revenue growth of approximately 24% from the 2023 first quarter. The Company has reduced its cost structure, simplified its processes, and has maintained continued momentum on its path to profitability. The following demonstrates the positive effects of XWELL’s actions to enhance its business model:Total cost of sales decreased approximately 7% from the 2023 first quarter. General and administrative expenses decreased approximately 47% from the 2023 first quarter. Total operating expenses decreased approximately 26% from the 2023...

NEWPORT BEACH, Calif., May 15, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB) (“Elevai” or the “Company”), a pioneering force in medical aesthetics, today reported financial results for the first quarter ended March 31, 2024. Elevai Labs CEO, Jordan R. Plews, PhD stated, “This quarter, Elevai Labs has demonstrated remarkable year-over-year revenue growth while significantly improving our gross margin, reflecting our commitment to optimizing production and stringent cost management. We remain focused on sustainable growth while enhancing our operational efficiencies and continuing to invest in innovation. These results underscore our adaptability and strategic foresight in meeting market demands.” Financial Results for the Three Months Ended March 31, 2024Revenue increased to $614,563 for the three months...

PHOENIX, May 15, 2024 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB: MFON), a provider of technology connecting mobile gaming audiences to real-world brands and products, today announced financial results for the first quarter (“Q1”) ending March 31, 2024. Recent Business HighlightsGrew consumer audience by more than 30% to over nine million consumers vs Q4 2023 Added 6 new brand partners including leaders in fuel and convenience and fast casual restaurants in Q1 2024 Increased conversion rate of audiences by 15% vs Q4 2023 Grew the number of mobile game titles by 83% vs Q4 2023 Appointed Bryce Daniels to the role of PresidentTom Akin, Mobivity Chairman of the Board of Directors, commented, “We are pleased to appoint Bryce Daniels to the role of President of Mobivity. Bryce has worked closely with the company over the last...

MARKHAM, Ontario, May 15, 2024 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) today reported results for the three months ended March 31, 2024. Results are presented in Canadian dollars unless otherwise noted. First Quarter 2024 HighlightsAdjusted EBITDA(1) excluding one-time items improved by $8.0 million to $20.3 million, largely driven by home health care volume growth, rate increases and growth in managed services. Home health care growth continued, with Q1 average daily volume (“ADV”) increasing to 29,007, up 11.4% from Q1 2023. LTC average occupancy increased 90 basis points (“bps”) to 97.5% from 96.6% Q1 2023. Extendicare Assist beds under management grew to 9,777, up 64.1% from Q1 2023, and SGP third-party and joint venture serviced beds increased by 23.7% from Q1 2023 to approximately...

• Posts Adjusted EBITDA Margin of 23.3% as a % of Revenue • Announced Normal Course Issuer Bid (“NCIB”) Subsequent to Quarter End CINCINNATI, May 15, 2024 (GLOBE NEWSWIRE) — Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S.-based home medical equipment provider, focused on end-to-end respiratory care, today announced its second quarter fiscal 2024 financial results and operational highlights. These results pertain to the three and six months ended March 31, 2024, and are reported in United States dollars (“$”, “dollars” and “US$”) and have been rounded to the nearest hundred thousand. Quipt will host its Earnings Conference Call on Thursday, May 16, 2024, at 10:00 a.m. (ET). The dial-in number is 1 (844) 763 8274 or 1 (647) 484 8814. The live audio webcast can be found...